Indivior Hit With Shareholder Suit Over Drug Revenue Forecasts

Indivior Plc was sued by an investor who alleges the drugmaker overstated the financial prospects for various products, including its flagship opioid addiction treatment Sublocade.

The proposed class action comes after Indivior in July cut its 2024 revenue forecast for Sublocade and Opvee, a nasal spray used in emergencies to reverse opioid overdoses. Indivior also said it would stop selling Perseris, a treatment for schizophrenia.

Indivior’s stock price fell almost 34% on the news, according to the complaint filed Friday in the US District Court for the Eastern District of Virginia.

Investors said it was “incredibly difficult” for the company ...